TrialBritish journal of haematology2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Yasuhiro Oki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.